This clinical trial tests an educational intervention called SunBeast, to improve ultraviolet (UV) knowledge and sun protective measures for ultrarunners at the Western States Endurance Run. Studies have shown that runners are at increased risk for skin cancer compared to the general population, often spending over 60 minutes in direct sunlight during training and races. Due to extensive outdoor exposure inherent to ultrarunning, this population faces an even greater risk for UV-induced skin damage and melanomas. Knowledge of skin cancer is positively associated with improved sun protection behaviors. The SunBeast intervention provides education targeted for ultrarunners. The SunBeast intervention may improve UV knowledge and sun protective measures for ultrarunners at the Western States Endurance Run.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07481344.
Locations matching your search criteria
United States
Michigan
Ann Arbor
University of Michigan Rogel Cancer CenterStatus: Temporarily closed to accrual
Contact: Scott Alan McLean
PRIMARY OBJECTIVE:
I. To implement and assess the impact of a pre-race targeted sun protection education program on training and race-day behaviors.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM I: Participants complete the SunBeast educational program, over 30 minutes, consisting of live, interactive online discussion and infographics/videos on skin cancer, UV index awareness, sunscreen use, protective clothing, and timing of runs. Participants also receive a text message or email once per month for up to 3 months prior to the race that contains education materials and links to the SunBeast website.
ARM II: Participants receive a general wellness brochure containing UV protection information and other general wellness topics. After the post race survey, participants will be invited to participate in the full SunBeast education program.
After completion of the study intervention, participants are followed up after the race.
Trial PhaseNo phase specified
Trial Typeprevention
Lead OrganizationUniversity of Michigan Rogel Cancer Center
Principal InvestigatorScott Alan McLean
